Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of Paulos, Chrystal
overview Our laboratory focuses on developing novel T-cell immunotherapies for patients with advanced cancer. Our strategy is based on the use of mouse models to develop human clinical trials that effectively harness the patient’s own immune system to kill cancer. We study new ways to improve adoptive cell transfer (ACT) therapy, which involves removal of T cells from the patient, their expansion/manipulation ex-vivo, followed by their return to patient preconditioned with lymphodepletion via chemotherapy agents and/or total body irradiation. Lymphodepletion significantly enhances the efficacy of ACT therapies. However, host conditioning with lymphodepletion is not the only factor that positively impacts clinical outcome. We and other investigators have found that the functional properties of T cells are critical for successful tumor immunotherapy. We have very recently found that CD4 and CD8 T cells that produce IL-17 (Th17 and Tc17 cells, respectively) mediate robust tumor regression. Additional investigation revealed that the expansion of Th17/Tc17 cells with the costimulatory molecule ICOS but not CD28 further improved their function and their ability to eradiate large tumors (see Fig1). Although ICOS-expanded Th17/Tc17 cells mediate potent tumor regression, the cellular, biochemical and molecular mechanisms underlying how ICOS signaling drives the differentiation and expansion of cells that produce high levels of IL-17, IL-21 and IFN-gamma compared to those stimulated with CD28 remains incompletely elucidated. Thus, we are now investigating key transcription factors regulated by ICOS versus CD28 that distinctly impact their functional fate. We are also investigating the mechanism governing the in vivo effectiveness of ICOS-expanded tumor-specific Tc17/Th17 cells using the clinically relevant transgenic ACT mouse models of cancer created in Dr. Nicholas Restifo’s laboratory. In summary, research in the Paulos laboratory will focus on broadening the utility and efficacy of the ACT approach. We are particularly interested in improving host preconditioning regimens as well as augmenting various T-cell subsets by ex-vivo and in-vivo manipulation with novel cytokine/chemical cocktails and with ICOS agonists (as well as with other costimulatory molecules). We believe that our investigations will provide vital information on how to build on the next generation of T-cell based immunotherapies for cancer as well as for autoimmunity and infectious diseases.
One or more keywords matched the following items that are connected to Paulos, Chrystal
Item TypeName
Academic Article Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Academic Article Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
Academic Article Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
Concept Adoptive Transfer
Academic Article Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.
Academic Article Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.
Academic Article Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.
Academic Article Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.
Academic Article Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis.
Academic Article Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.
Academic Article When worlds collide: Th17 and Treg cells in cancer and autoimmunity.
Academic Article Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.
Academic Article In Vitro Priming of Adoptively Transferred T Cells with a ROR? Agonist Confers Durable Memory and Stemness In Vivo.
Search Criteria
  • Adoptive Transfer